ADA 2026 Standards of Care – Diagnostic Algorithm for Risk Stratification and Prevention of Cirrhosis in MASLD
American Diabetes Association 2026 (Section 4) screening pathway for adults with type 2 diabetes, prediabetes, or obesity with cardiovascular risk factors.
Type 2 diabetes is one of the strongest accelerators of liver scarring, which is why the American Diabetes Association's 2026 Standards of Care builds liver fibrosis screening directly into routine diabetes visits. Even if your ALT and AST liver enzymes look completely normal, having type 2 diabetes, prediabetes, or obesity with a heart risk factor puts you in the group that benefits most from checking FIB-4 every 1 to 2 years — and moving to a FibroScan (8.0 kPa cutoff) or ELF test (9.8 cutoff) whenever FIB-4 is 1.3 or higher.
ADA 2026 Stepwise Screening & Referral Pathway (Section 4)
Evaluate alcohol intake (MetALD/PEth), steatogenic medications, viral hepatitis, iron, AAT, or autoimmune conditions.
(Or ELF™ ≥9.8 if elastography is unavailablea)
- Repeat FIB-4 every 1–2 years
- Optimize lifestyle, ASCVD risk (statins safe!), and prioritize glucose/obesity therapies with MASH benefit (GLP-1 or dual GIP/GLP-1 RAs, pioglitazone)
- Advanced NIT / MRE staging & biopsy-free F2–F3 MASH pharmacotherapy (eg, resmetirom, semaglutide 2.4 mg)
- Long-term cirrhosis & HCC surveillance if F4